Matinas BioPharma Holdings, Inc.(MTNB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.2M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MTNB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Matinas BioPharma Holdings, Inc. (MTNB), a Healthcare sector company. MTNB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Matinas BioPharma Holdings, Inc. reports net income of $-1.9M, free cash flow of $-1.6M. Top institutional holders of MTNB by reported 13-F value include GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, BlackRock,, based on the most recent SEC filings. MTNB trades on the NYSE exchange and files with the SEC under CIK 1582554. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MTNB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Matinas BioPharma Holdings, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-1.9M
Free Cash Flow
Q1 2026
$-1.6M
Get alerted when MTNB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Matinas BioPharma Holdings, Inc. including:
Top Institutional Holders of MTNB
GEODE CAPITAL MANAGEMENT, LLC
$32.6K65,170 shCITADEL ADVISORS LLC
$25.8K51,698 shBlackRock, Inc.
$24.8K49,650 shVANGUARD CAPITAL MANAGEMENT LLC
$20.1K40,110 shHolos Integrated Wealth LLC
$16.3K32,480 shRENAISSANCE TECHNOLOGIES LLC
$14.3K28,570 shXTX Topco Ltd
$10.4K20,706 shVANGUARD FIDUCIARY TRUST CO
$9.1K18,277 shSTATE STREET CORP
$7.7K15,322 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$7.2K14,328 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $32.6K | 65,170 |
| CITADEL ADVISORS LLC | $25.8K | 51,698 |
| BlackRock, Inc. | $24.8K | 49,650 |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.1K | 40,110 |
| Holos Integrated Wealth LLC | $16.3K | 32,480 |
| RENAISSANCE TECHNOLOGIES LLC | $14.3K | 28,570 |
| XTX Topco Ltd | $10.4K | 20,706 |
| VANGUARD FIDUCIARY TRUST CO | $9.1K | 18,277 |
| STATE STREET CORP | $7.7K | 15,322 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.2K | 14,328 |
More Healthcare Companies
View all Healthcare →Put MTNB on your watchlist
Track score changes the day Matinas BioPharma Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MTNB a good stock to buy?
13F Pro's AI-powered analysis of Matinas BioPharma Holdings, Inc. (MTNB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MTNB are available on the MTNB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MTNB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MTNB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Matinas BioPharma Holdings, Inc.'s investment landscape.